| 刊名 | Medicinal Plant |
| 作者 | Yan CHEN， Xianglin LI， Lei LIU， Xueyuan FENG， Yuxuan HU， Zhengxin ZHANG， Long CHEN， Xiujun LIANG， Qian XU |
| 作者单位 | Institute of Basic Medical Research, Chengde Medical University； Clinical Laboratory, The Affiliated Hospital of Chengde Medical University； Department of Immunology, Chengde Medical University |
| DOI | 10.19601/j.cnki.issn2152-3924.2025.04.001 |
| 年份 | 2025 |
| 刊期 | 4 |
| 页码 | 1-5，11 |
| 关键词 | Ailanthone, Non-small cell lung cancer, Cisplatin resistance, Autophagy |
| 摘要 | [Objectives] To investigate whether Ailanthone (AIL) could reverse cisplatin resistance in non-small cell lung cancer (NSCLC) by modulating autophagy pathways in A549/DDP cells. [Methods] Cisplatin-resistant A549/DDP cells were treated with AIL (0.6 μmol/L), cisplatin (50 μg/mL), or their combination. Cell proliferation was assessed by MTT, EdU and colony formation assays; migration by Transwell and wound healing assays; autophagy markers (P62, LC3B, Beclin1, ATG5) by Western blot; LC3B puncta by immunofluorescence; with rescue experiments using rapamycin. [Results] The AIL-cisplatin combination synergistically inhibited proliferation and migration, while downregulating P-gp and MVP. AIL significantly increased P62 accumulation while decreasing LC3B-II, Beclin1 and ATG5. Rapamycin reversed these effects, restoring viability and resistance markers. [Conclusions] AIL reverses cisplatin resistance in NSCLC by inhibiting autophagy through P62/LC3B regulation, offering a promising therapeutic strategy for refractory NSCLC. |
